Drug details

Beovu (brolucizumab-dbll for intravitreal injection)

type of Macular Degeneration Agents

Beovu (brolucizumab-dbll) Injection is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD).

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• eye pain,
• tunnel vision,
• seeing halos around lights,
• increased sensitivity to light,
• eye redness,
• swelling around your eyes,
• discharge or bleeding from the eye,
• seeing “floaters” in your vision,
• decreased vision,
• sudden numbness or weakness, and
• problems with speech or balance

The following drugs are related to Beovu, either as a replacement or used together:

• Eylea (aflibercept)
• Eylea HD (aflibercept injection)
• Avastin (bevacizumab)
• Byooviz (ranibizumab-nuna injection, for intravitreal use)
• Cimerli (ranibizumab-eqrn injection)
• Vabysmo (faricimab-svoa injection)
• Lucentis (ranibizumab injection)
• Syfovre (pegcetacoplan injection, for intravitreal use)
• Susvimo (ranibizumab injection)